2018-09-15

Big news! China's century-old pharmaceutical giant is entering the stem-cell industry, paving the way for a new era in China's stem-cell-based drug development!

Source: Stem Cell Home On September 14, 2018, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (referred to as Jiuzhitang Maker), established by Jiuzhitang, a traditional Chinese medicine pharmaceutical company, signed an investment agreement with U.S.-based Stemedica Cell Technologies, Inc., a California-based biopharmaceutical company located in San Diego’s Biotech Valley and boasting over a decade of experience in stem cell research, development, manufacturing, and marketing. Under the terms of the agreement, Jiuzhitang Maker will introduce cutting-edge stem cell production technologies and a state-of-the-art preparation platform from one of the world’s leading stem cell companies. Over the next 3 to 5 years, the company plans to build a commercial-grade stem cell production facility meeting both U.S. and EU cGMP standards at the Beijing Daxing Biomedical Industry Base. This strategic move marks Jiuzhitang, a century-old Chinese medicine enterprise, officially entering the rapidly growing fields of stem cell drug research, clinical applications, and industrialization—signaling that China’s era of stem cell-based pharmaceuticals is on the horizon.

2018-09-15

"The Global Stem Cell Industry Development Summit" Points the Way Forward for Future Medical Advancements

Source: Physician News On September 14, 2018, the "Global Stem Cell Industry Development Summit Forum" was held in Beijing. As a key focus of future medical research, stem cell technology has been continuously included in multiple national and regional science and technology development plans and specialized guidelines over the years.

2018-09-15

From stem cell research to stem cell-based pharmaceuticals: Jiuzhitang Invests in Regenerative Medicine

Source: Securities Times (Reporter Wang Xiaowei) Jiuzhitang has launched the Jiuzhitang Yonghe Qihang Fund, which on the 14th signed an investment agreement with Stemedica Cell Technology Co., Ltd., based in San Diego, the "Biotech Valley" of the U.S. According to the agreement, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereinafter referred to as Jiuzhitang Maker) will introduce cutting-edge stem cell production technologies and a state-of-the-art preparation platform from a globally leading stem cell company. Over the next 3 to 5 years, Jiuzhitang Maker plans to establish a commercial-grade stem cell production facility meeting both U.S. and EU cGMP standards at the Daxing Biomedical Industry Base in Beijing. This move marks Jiuzhitang, a time-honored Chinese medicine enterprise with over a century of history, officially entering the rapidly growing stem cell industry.

2018-09-15

Multiple major companies enter the market, accelerating the launch of China's stem-cell drugs.

Source: Science and Technology Daily Another major development has emerged in China's stem cell therapy field. On September 14, traditional Chinese medicine pharmaceutical company Jiuzhi Tang announced that Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereafter referred to as Jiuzhitang Maker) will partner with U.S.-based Stemedica Cell Technology Co., Ltd., a company with over a decade of experience in stem cell R&D and manufacturing. Together, they plan to build a commercial-grade stem cell production facility meeting both U.S. and EU cGMP standards within the next 3 to 5 years. This strategic move marks Jiuzhi Tang's official entry into the stem cell industry. "Our goal is to develop stem cell-based therapeutic drugs," Jiuzhitang Maker CEO Gao Yansong told a reporter from Science and Technology Daily.

2018-09-15

Jiuzhitang's stem-cell drug R&D and production base is expected to be operational by 2019.

Source: China.org.cn September 17 (Reporter Du Ding) – Jiuzhitang is making a strategic move into the research, clinical development, and industrialization of stem cell therapies. Recently, Jiuzhitang’s newly established Jiuzhitang Yonghe Qihang Fund signed an investment agreement with U.S.-based Stemedica Cell Technologies Inc. Through this collaboration, Jiuzhitang will introduce cutting-edge stem cell production technologies and a robust manufacturing platform, aiming to build a commercial-grade stem cell production facility meeting both U.S. and EU cGMP standards within 3 to 5 years at the Beijing Daxing Biomedical Industry Base. Li Zhenguo, Chairman of Jiuzhitang, emphasized that the intrinsic value of traditional Chinese medicine remains largely untapped. He expressed the company’s ambition to leverage its strong position in the Chinese pharmaceutical industry as it ventures into the promising field of stem cell technology.

2018-09-14

Jiuzhitang Maker signs a "Joint Construction Agreement for a Stem Cell Clinical Research Base" with Beijing Tiantan Hospital.

In September 2018, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. signed a "Joint Construction Agreement for a Stem Cell Clinical Research Base" with Beijing Tiantan Hospital, Affiliated to Capital Medical University.

2018-09-14

From "stem cell research" to "stem cell pharmaceuticals": Century-old Jiuzhitang—Pioneering Global Regenerative Medicine

Source: BioValley On September 14, 2018, Jiuzhitang Maker Cell Technology Co., Ltd. (hereafter referred to as Jiuzhitang Maker), established by the traditional Chinese medicine pharmaceutical company Jiuzhitang, signed an investment agreement with U.S.-based Stemedica Cell Technologies, Inc. (referred to as U.S. Stemedica), a biopharmaceutical company based in San Diego's Biotech Valley and boasting over a decade of experience in stem cell research, development, manufacturing, and marketing. According to the agreement, Jiuzhitang Maker will introduce cutting-edge stem cell production technologies and a state-of-the-art preparation platform from one of the world’s leading stem cell companies, aiming to establish operations within three to five years at the Beijing Daxing Biomedical Industry Base.

2018-07-17

Jiuzhitang Maker's production base in Daxing District has passed environmental protection inspection.

On July 17, 2018, the R&D and production base of Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd., located in Daxing District, Beijing, successfully passed the environmental protection inspection conducted by the Daxing District Environmental Protection Bureau, signaling its readiness for future research and development as well as the production of stem-cell-based pharmaceuticals.

2018-05-21

Chairman and Vice President of Jiuzhitang Co., Ltd., as well as Chairman and CEO of Meike, visited the Kazakhstan National Scientific Medical Center.

On May 21, 2018, Li Zhenguo, Chairman of Jiuzhi堂 Co., Ltd., along with Vice President Liu Guochao, and Zhang Quancheng, Chairman, and Gao Yansong, CEO of Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd., visited the Kazakhstan National Scientific Medical Center and CITIC Group’s Astana Medical Clinic, where they finalized the basic framework for future collaboration.